Table 2

Risk factors for longer continuous QTc duration (Framingham) among all 1426 participants* in univariate (model 1), partially adjusted (model 2) and fully adjusted (model 3) analyses

	Model 1		Model 2		Model 3
	Mean difference (95% CI)	P value	Mean difference (95% CI)	P values	Mean difference (95% CI)	P values
HIV infected (vs uninfected)	0.7 (−1.3 to 2.8)	0.48	3.4 (1.3 to 5.5)	0.001	4.0 (1.8 to 6.1)	<0.001
Age per 5 years			2.4 (1.9 to 2.9)	<0.001	2.2 (1.5 to 2.8)	<0.001
Race
Black (vs Caucasian)			−0.5 (− 3.2to 2.1)	0.70	−1.2 (− 3.8 to 1.5)	0.39
Hispanic/other (vs Caucasian)			0.3 (− 3.0 to 3.6)	0.86	0.5 (−2.8 to 3.8)	0.76
Enrolled after 2001			1.6 (−1.2 to 4.4)	0.25	1.1 (−1.7 to3.8)	0.46
Body mass index (kg/m²)					2.0 (1.0 to 3.1)	<0.001
Alcohol use >13 drinks per week					5.0 (1.5 to 8.5)	0.005
Cumulative pack-year of smoking					0.0 (−0.1 to 0.0)	0.63
Opioid use					2.3 (−1.4 to 6.1)	0.22
Systolic blood pressure (mm Hg)					1.1 (0.5 to 1.8)	0.001
Fasting glucose (mg/dL)					−0.2 (−0.6 to 0.2)	0.26
On hypertension medications					2.6 (0.3 to 4.8)	0.027
On diabetes medications					−1.5 (−5.5 to 2.5)	0.47
eGFR per mL/min/1.73 m²					0.0 (−0.1 to 0.1)	1.00
LVH on ECG (Cornell voltage)					16.6 (8.1 to 25)	<0.001
QT prolongation drugs (known+possible vs conditional+none)					2.5 (−0.8 to 5.8)	0.13

*Models 2 and 3 further controlled for MACS enrolment site.
MACS, Multicenter AIDS Cohort Study; QTc, corrected QT interval.